Published: Sep 3rd, 2013
Walgreens just made it easier for JDRF supporters to stay happy and healthy this flu season and support type 1 diabetes (T1D) research at the same time. Just stop in your favorite Walgreens or Duane Reade for your flu shot between Sept. 1 and Oct. 31, 2013, and Walgreens will donate $1 to JDRF for every flu shot its supporters get. You’ll be helping to reduce your risks from the flu and potential complications, while at the same time helping to find a cure for T1D. View the flier.
Published: Aug 27th, 2013
CDC data show that 44% of U.S. school districts had bans on junk foods from vending machines in 2012, an increase from 30% in 2006. Researchers also found that the percentage of districts that allowed soda advertisements in schools decreased from about 47% in 2006 to 33.5% in 2012, while the number of school districts that disclosed nutritional and caloric information of school meals to families grew from about 35% in 2000 to about 53% last year. Read more.
Published: Aug 27th, 2013
A $600,000 grant will allow the University of Florida to renovate existing lab space into a laboratory dedicated solely to producing more effective treatments to prevent vision loss and blindness. “Having this laboratory space will significantly enhance our ability to conduct essential research into the basic mechanisms of normal vision and disease. It also will offer the resources to develop translational projects that will create new therapies for diabetic retinopathy…and other retinal degenerations.” Read more.
Published: Aug 26th, 2013
The University of Florida recently celebrated the opening of the Clinical and Translational Research Building, a new home for research that will speed scientific discoveries to patients. The building houses an array of academic departments, clinical research programs, and Institutes including the Clinical and Translational Science Institute and, the UF Institute on Aging which focuses, in part, on the link(s) between diabetes and Alzheimer’s disease. Read more.
Published: Aug 21st, 2013
Neuropathy is a serious and sometimes overlooked problem for patients with diabetes. The American Diabetes Associations estimates that 60-70% of diabetics have mild to severe nervous system damage. Learn how drug manufacturer Shire is educating everyone about a new risk assesment tool in addition to complications associated with having diabetes. Learn more.
Published: Aug 9th, 2013
Type 1 diabetes patients who were on teplizumab, an experimental treatment, were able to maintain their insulin production rates for two years, longer than patients on most other diabetes medications, according to data from a Phase II study published in Diabetes. However, about half of patients did not benefit from the drug. Researchers said patients who saw the most benefit were those who still had good glucose control and moderate insulin requirements at the start of the study.
Published: Aug 1st, 2013
UF&Shands, the University of Florida Academic Health Center, is now University of Florida Health. The new umbrella term reflects the health system’s strong ties to UF, a key part of what differentiates the academic health center — with its focus on excellence in research, teaching and patient care — from its competitors. See how invisible connections are making a difference in the lives of every patient we serve.
Published: Jul 30th, 2013
Today, the insulin that comes in vials, pens, and pumps is not from pigs and cows but from pharmaceutical companies armed with the latest groundbreaking biotechnology. Join Diabetes Forecast Magazine for a behind-the-scenes look at the making of this lifesaving medication.
Published: Jul 19th, 2013
WellDoc has announced the launch of BlueStar, an FDA approved prescription version of its “Diabetes Manager” program. BlueStar is the first disease therapy system to be prescribed through an app. WellDoc was designed for people with type 2 diabetes. The goal of this new mobile technology is to educate patients about type 2 diabetes and keep them engaged in their disease management. WellDoc is the first app to be eligible for reimbursement. Learn more.
Published: Jul 17th, 2013
A study in Cell Transplantation found type 2 diabetes patients who received autologous bone marrow stem cells required lower insulin doses compared with those in the control group. Longer-duration studies with a larger number of participants will be needed to establish the efficacy of stem cell treatment in diabetes, researchers said. Read more.